Abstracts

Single-Agent TDF Versus Combination FTC/TDF PrEP Among Heterosexual Men and Women

Background: Antiretroviral pre-exposure prophylaxis (PrEP), using daily oral tenofovir (TDF) alone or combination emtricitabine/tenofovir (FTC/TDF), has been demonstrated to be an efficacious HIV-1 prevention intervention in four clinical trials. Whether single-agent TDF PrEP has comparable efficacy to dual-agent FTC/TDF PrEP is unknown. Methodology: The Partners PrEP Study was a randomized, double-blind, placebo-controlled three-arm trial of…

Divergent Adherence Estimates With Pharmacokinetic and Behavioral Measures in VOICE (MTN003)

Background: The level of protection conferred by tenofovir (TFV)-based PrEP correlates with product adherence in some studies. In VOICE, daily oral tenofovir disoproxil fumarate (TDF), oral TDF-emtricitabine (FTC), and 1% vaginal TFV gel were not effective and poor adherence was determined based on plasma TFV detection in a subset of participants in the active product…

Transmitted HIV-1 Drug Resistance Among Men Who Have Sex With Men, 11 US Jurisdictions, 2008–2011

Background: Men who have sex with men (MSM) bear the heaviest burden of HIV in the United States. Effective antiretroviral therapy (ART) is crucial for viral suppression and reduced transmission. We used National HIV Surveillance System data to assess the prevalence of transmitted drug resistance among MSM. Methodology: We analyzed HIV-1 pol sequences among persons…

Impact of Transmitted Drug Resistance on Susceptibility to First-Line HAART in France (2010-2012)

Background: As recommended by the ANRS program for HIV-1 resistance surveillance, we estimated prevalence of transmitted drug resistance mutations (RAMs) and the evolution of the viral molecular epidemiology in primary HIV-1-infected patients in France. Methodology: 796 primary HIV-1-infected patients were included in 2010-2012 (404 from the AC11 ANRS Group, 302 from the PRIMO Cohort and…

Current First-Line Regimens Are Effective in Patients With Single Transmitted TAM

Background: Currently the most prevalent transmitted resistance-associated mutations in Western European countries are Thymidine Analogue Mutations (TAMs). We hypothesize that in contrast to previously published data these mutations do not affect the efficacy of currently recommended first line combination antiretroviral therapy (cART) regimens with a low barrier to resistance development (GBR) (two NRTI and one…

Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated With Fitness Costs

Background: Transmitted HIV-1 drug resistance mutations (TDR) can impair antiretroviral treatment (ART) but the persistence of many TDRs is poorly understood. We determined persistence times for TDR in treatment-naive patients from longitudinal genotypic resistance tests (GRT) from the Swiss HIV Cohort Study Drug Resistance Database, and compared persistence times with fitness cost of TDRs. Methodology:…

Antiretroviral Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men in the US

Background: In the United States (US), Black men who have sex with men (MSM) are disproportionately affected by HIV. Understanding the current prevalence and patterns of antiretroviral (ARV) drug resistance in this population is important since ARV drug resistance can lead to treatment failure and limit treatment options. We analyzed ARV drug resistance among Black…

Primary Resistance to Integrase Strand-Transfer Inhibitors in Europe

Background: Primary HIV-1 resistance can compromise the efficacy of antiretroviral therapy (ART). The prevalence of primary resistance to integrase strand-transfer inhibitors (INSTI) in recently HIV-1-infected subjects remains unknown. Methodology: This was a multicenter cross-sectional study within the European SPREAD surveillance programme which continuously collects data from a representative set of newly diagnosed patients. A representative…